INT320160

Context Info Confidence 0.00 First Reported 2008 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 1 Disease Relevance 0.35 Pain Relevance 0.06

extracellular region (FCER2, IGHG3) plasma membrane (FCER2)

FCER2 (Homo sapiens) IGHG3 (Homo sapiens)

Pain Link Frequency Relevance Heat Inflammatory mediators 2 72.64 corticosteroid 38 54.32 agonist 9 5.00 Inflammation 5 5.00 headache 2 5.00 cytokine 1 5.00 withdrawal 1 5.00 Pain 1 5.00 Antihistamine 1 5.00 antagonist 1 5.00

Disease Link Frequency Relevance Heat Asthma 148 97.96 INFLAMMATION 7 72.64 Clinical Trials And Case Reports 9 5.00 Emergencies 9 5.00 Disease 8 5.00 Hypersensitivity 6 5.00 Anaphylaxis 6 5.00 Urticaria 4 5.00 Occupational Lung Diseases 3 5.00 Airway Obstruction 2 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Omalizumab (Xolair®, Novartis Pharma AG) is a recombinant DNA-derived humanized immunoglobulin G (IgG) 1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and has been developed for the treatment of allergic asthma.

immunoglobulin E Binding (binds) of IgG associated with asthma

1) Confidence 0.00 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899803 Disease Relevance 0.35 Pain Relevance 0.06

General Comments

This test has worked.